Cargando…
Platelet-rich plasma in patients affected with Peyronie’s disease
OBJECTIVES: The objective of our study is to discover and evaluate the effects of repeated intralesional injections inside the tunica albuginea of platelet-rich plasma (PRP) in the treatment of Peyronie’s disease (PD). METHODS: As part of a prospective study over 12 months from February 2020 until F...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10208162/ https://www.ncbi.nlm.nih.gov/pubmed/37234679 http://dx.doi.org/10.1080/2090598X.2022.2135284 |
_version_ | 1785046613165604864 |
---|---|
author | Achraf, Chatar Abdelghani, Pr Ammani Jihad, Pr El Anzaoui |
author_facet | Achraf, Chatar Abdelghani, Pr Ammani Jihad, Pr El Anzaoui |
author_sort | Achraf, Chatar |
collection | PubMed |
description | OBJECTIVES: The objective of our study is to discover and evaluate the effects of repeated intralesional injections inside the tunica albuginea of platelet-rich plasma (PRP) in the treatment of Peyronie’s disease (PD). METHODS: As part of a prospective study over 12 months from February 2020 until February 2021, on Sixty-five patients with Peyronie’s disease, and penile curvature between 25 and 45°. Patients were stratified into two groups, the first with a curvature between 25 and 35° and the second between 35 and 45°. Gathered data included patient-demographics, Injection technique, outcomes: both quantitative (curvature assessments) and qualitative (state of erectile function, pain during intercourse), and complications. RESULTS: Patients in both groups received an average of 6.1 injections of PRP during the study period. Angulation was significantly improved in both groups an average final improvement of 16.88° (SD = 3.35) (p < 0.001) in the first group and 17.27° (SD = 4.22) (p < 0.001) in the second group. Pain during sex decreased from 70.7% to 34.25%, and 55.5% of patients had easier sexual intercourse. CONCLUSIONS: The positive results of our series of treatment for Peyronie’s disease by injection of platelet-rich plasma are encouraging both methodologically (simplicity) and clinical (safety and efficacy) as well as patient satisfaction. |
format | Online Article Text |
id | pubmed-10208162 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-102081622023-05-25 Platelet-rich plasma in patients affected with Peyronie’s disease Achraf, Chatar Abdelghani, Pr Ammani Jihad, Pr El Anzaoui Arab J Urol Andrology and Sexual Medicine OBJECTIVES: The objective of our study is to discover and evaluate the effects of repeated intralesional injections inside the tunica albuginea of platelet-rich plasma (PRP) in the treatment of Peyronie’s disease (PD). METHODS: As part of a prospective study over 12 months from February 2020 until February 2021, on Sixty-five patients with Peyronie’s disease, and penile curvature between 25 and 45°. Patients were stratified into two groups, the first with a curvature between 25 and 35° and the second between 35 and 45°. Gathered data included patient-demographics, Injection technique, outcomes: both quantitative (curvature assessments) and qualitative (state of erectile function, pain during intercourse), and complications. RESULTS: Patients in both groups received an average of 6.1 injections of PRP during the study period. Angulation was significantly improved in both groups an average final improvement of 16.88° (SD = 3.35) (p < 0.001) in the first group and 17.27° (SD = 4.22) (p < 0.001) in the second group. Pain during sex decreased from 70.7% to 34.25%, and 55.5% of patients had easier sexual intercourse. CONCLUSIONS: The positive results of our series of treatment for Peyronie’s disease by injection of platelet-rich plasma are encouraging both methodologically (simplicity) and clinical (safety and efficacy) as well as patient satisfaction. Taylor & Francis 2022-10-25 /pmc/articles/PMC10208162/ /pubmed/37234679 http://dx.doi.org/10.1080/2090598X.2022.2135284 Text en © 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Andrology and Sexual Medicine Achraf, Chatar Abdelghani, Pr Ammani Jihad, Pr El Anzaoui Platelet-rich plasma in patients affected with Peyronie’s disease |
title | Platelet-rich plasma in patients affected with Peyronie’s disease |
title_full | Platelet-rich plasma in patients affected with Peyronie’s disease |
title_fullStr | Platelet-rich plasma in patients affected with Peyronie’s disease |
title_full_unstemmed | Platelet-rich plasma in patients affected with Peyronie’s disease |
title_short | Platelet-rich plasma in patients affected with Peyronie’s disease |
title_sort | platelet-rich plasma in patients affected with peyronie’s disease |
topic | Andrology and Sexual Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10208162/ https://www.ncbi.nlm.nih.gov/pubmed/37234679 http://dx.doi.org/10.1080/2090598X.2022.2135284 |
work_keys_str_mv | AT achrafchatar plateletrichplasmainpatientsaffectedwithpeyroniesdisease AT abdelghaniprammani plateletrichplasmainpatientsaffectedwithpeyroniesdisease AT jihadprelanzaoui plateletrichplasmainpatientsaffectedwithpeyroniesdisease |